Dianthus Therapeutics, Inc. $DNTH Shares Acquired by Sei Investments Co.

Posted by Stanley Muller on Aug 3rd, 2026

Sei Investments Co. grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 566.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,229 shares of the company’s stock after buying an additional 78,388 shares during the period. Sei Investments Co.’s holdings in Dianthus Therapeutics were worth $7,741,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares during the last quarter. American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after acquiring an additional 6,323 shares during the period. Invesco Ltd. raised its stake in Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after acquiring an additional 4,962 shares during the last quarter. Alliancebernstein L.P. lifted its position in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after acquiring an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at about $27,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $106.92 on Monday. The stock has a 50-day simple moving average of $92.63 and a two-hundred day simple moving average of $78.62. The firm has a market capitalization of $5.84 billion, a P/E ratio of -25.89 and a beta of 1.20. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on DNTH shares. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush increased their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.

Check Out Our Latest Stock Report on DNTH

About Dianthus Therapeutics

(Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.